title: Is there a role for inhaled nitric oxide in pediatric ARDS?
abstract: Despite advances in ventilator management and use of extracorporeal lung support, mortality related to ARDS in pediatric patients has not been reduced over the past 20 years. Progressive respiratory failure, due to evolution of the primary illness or to complications of ventilator therapy, significantly contributes to poor outcome. ARDS is characterized by severe ventilation-perfusion mismatch and by pulmonary hypertension. Because of their side effects which affect systemic hemodynamic status or worsen intrapulmonary shunting, intravenous vasodilator trials have been of limited interest. Nitric oxide (NO) has been recognized as a gas with vasodilator properties. In neonates studies have shown that inhaled NO may have an important role in the therapy of persistent pulmonary hypertension. Inhaled NO in adults with severe ARDS has been shown to reduce pulmonary hypertension without producing systemic vasodilation. This reduction of pulmonary vascular resistances may reduce pulmonary edema formation, decrease vasoconstrictor response to cardiotonic agents, and improve biventricular function. In addition, arterial oxygenation seems to be increased by improved matching of ventilation with perfusion. Improvement of oxygenation with inhaled NO suggests that use of lower tidal volumes and FIO2 may be more successful. Until now, there are no published studies regarding NO administration in ARDS affecting nonneonatal pediatric patients. However, the results obtained in adults and newborns suggest that inhaled NO may be a useful adjuvant therapy of ARDS in children, possibly in association with other therapies. Even in adults it remains unclear whether therapy with inhaled NO can reduce morbidity and mortality. Prospectives and randomized studies are essential to assess the real utility of inhaled NO in ARDS.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Réanimation Pédiatrique, Hôpital Robert Debré, Paris, France.
authors.forename: J F
authors.initials: JF
authors.lastname: Germain
authors.forename: J C
authors.initials: JC
authors.lastname: Mercier
authors.forename: I
authors.initials: I
authors.lastname: Casadevall
authors.forename: L
authors.initials: L
authors.lastname: Desplanques
authors.forename: J F
authors.initials: JF
authors.lastname: Hartmann
authors.forename: F
authors.initials: F
authors.lastname: Beaufils
mesh_terms: D000280:Administration, Inhalation; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D009569:Nitric Oxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D009569:Nitric Oxide